Here’s what you should know.
1. Providers use the products to treat ocular surgery patients’ postoperative pain and inflammation.
2. Valeant secured a product license in 2015.
3. Valeant CEO Joseph Papa said, “We are pleased to extend our relationship with EyeGate, and to obtain the global commercial and manufacturing rights to the EyeGate II Delivery System for the indication of postoperative inflammation and pain in ocular surgery patients.”
4. Mr. Papa said the products have “significant potential” as part of the Bausch + Lomb, Valeant’s eye care division.
More articles on improving health:
Healthcare data breaches up 40% in 2016, hitting 15.9M patient records: 5 key points
Protesters meet Republicans at town halls across the country, spar over healthcare
5 legislative changes for ASC leaders to note — Feb. 22, 2017
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
